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Abstract
Multiple sclerosis (MS) is a debilitating inflammatory disease of the central nervous system (CNS) characterized by local
destruction of the insulating myelin surrounding neuronal axons. With more than 200 million MS patients worldwide, the
absence of treatments that prevent progression or induce repair poses a major challenge. Anti-inflammatory therapies have
met with limited success only in preventing relapses. Previous screening of human serum samples revealed natural IgM
antibodies that bind oligodendrocytes and promote both cell signaling and remyelination of CNS lesions in an MS model
involving chronic infection of susceptible mice by Theiler’s encephalomyelitis virus and in the lysolecithin model of focal
demyelination. This intriguing result raises the possibility that molecules with binding specificity for oligodendrocytes or
myelin components may promote therapeutic remyelination in MS. Because of the size and complexity of IgM antibodies, it
is of interest to identify smaller myelin-specific molecules with the ability to promote remyelination in vivo. Here we show
that a 40-nucleotide single-stranded DNA aptamer selected for affinity to murine myelin shows this property. This aptamer
binds multiple myelin components in vitro. Peritoneal injection of this aptamer results in distribution to CNS tissues and
promotes remyelination of CNS lesions in mice infected by Theiler’s virus. Interestingly, the selected DNA aptamer contains
guanosine-rich sequences predicted to induce folding involving guanosine quartet structures. Relative to monoclonal
antibodies, DNA aptamers are small, stable, and non-immunogenic, suggesting new possibilities for MS treatment.
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Introduction
MS is a debilitating neurological disease with a prevalence of
about 0.1% in the Western world [1]. Though studied for more
than 150 years, the causes of this apparent immune-mediated
disorder remain unknown. Distinct patterns of MS disease have
been discerned [2], and the uneven geographical distribution of
MS cases is perplexing. MS is fundamentally an inflammatory
disease leading to CNS lesions characterized by the loss of myelin
required for electrical insulation of neuronal axons [3,4]. Resulting
symptoms, including fatigue, gait impairment, cognitive impair-
ment, and vision loss, can lead to permanent disability [5].
Hypotheses for MS causation include autoimmune, genetic,
environmental, and infectious factors, though no consensus has
been reached.
While the origin of MS remains unresolved, therapy and cure
present even more urgent challenges. Therapies for relapsing MS
include plasma exchange to remove pathogenic immunoglobulins
and/or treatment with anti-inflammatory drugs such as glatiramer
acetate, b interferon, mitoxantrone, and natalizumab [6]. These
approaches are not curative, and are ineffective in some cases [7].
It remains unclear whether curative therapy should be directed
against the immune system, or toward repair and rescue of
oligodendrocytes and myelin.
A fortuitous observation led to the discovery of antibodies that
promote remyelination [8]. In these studies, passive transfer of
antisera induced by immunization of mice with myelin was
observed to promote remyelination in MS-like lesions induced by
chronic infection by Theiler’s encephalomyelitis virus (TMEV),
suggesting a therapeutic role for anti-myelin antibodies. Similar
results were obtained in the lysolecithin model of focal demyelin-
ation [9]. Subsequent screening led to the identification of multiple
natural murine and human IgM autoantibodies that bind to live
cerebellum and cultured oligodendrocytes and promote remyeli-
nation in mice [8]. Target antigens are not known in molecular
detail, but the pentavalent character of the IgM antibody is
important for activity [10]. A recombinant form of one such IgM
antibody, sHIgM22, is in preclinical development. Because some
myelin-specific ligands bind oligodendrocytes and promote
remyelination in MS lesions, we are seeking alternative agents
that are smaller and more robust than IgM monoclonal antibodies.
In the present study we applied in vitro selection to identify a small
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single-stranded DNA aptamer with affinity for myelin and the
ability to promote remyelination in mice (Fig. S1).
Aptamers are folded, single-stranded nucleic acids with activities
that, like folded proteins, depend on their three-dimensional
shapes and surface features [11,12]. Although RNA and DNA
aptamers are under investigation in a variety of therapeutic
contexts [13], their potential has not been fully explored. Potential
advantages of aptamers relative to antibodies include their much
smaller size, greater chemical stability, ease of synthesis, and lack
of immunogenicity. A fundamental advantage of aptamers is the
availability of in vitro selection technology wherein cycles of affinity
selection and amplification can identify nucleic acids with rare
properties from vast random libraries containing 1014 or more
candidates [14]. Such chemical diversity exceeds that encoded in
mammalian immune systems, and the selection process takes place
in vitro.
Results and Discussion
We used in vitro selection from a single-stranded DNA library to
identify aptamers that bound to a suspension of crude murine
myelin (Fig. 1, Fig. S2, S3, S4). The procedure (Fig. 1A) yielded
DNA molecules that were sequenced. A resulting anti-myelin
aptamer 3064 (Fig. 1B-C) was compared with negative control
aptamers 3060 (Fig. 1D) and 3202 (Fig. 1E). Interestingly, and as
previously observed for some other DNA aptamers [15–17], both
aptamer 3064 (specific for myelin) and control aptamer 3060
(selected for affinity to recombinant Myelin Oligodendrocyte
Glycoprotein (MOG), but also showing the ability to bind chelated
Nickel ions [18]) contain guanosine-rich domains predicted to
induce intra- or intermolecular folding through guanosine
quartets.
We analyzed the specificity of anti-myelin DNA aptamer 3064
and controls 3060 and 3202 by assessing the binding of fluorescent
aptamers to crude myelin protein suspension using centrifugal
sedimentation to recover bound aptamers (Fig. 2A). Myelin-
specific aptamer 3064 showed strong myelin-dependent binding
while aptamers 3060 and 3202 did not. Because the myelin
preparation is a crude mixture of proteins and lipids, these results
cannot provide quantitative affinity estimates. To further assess
specificity, crude myelin proteins were separated by SDS-
polyacrylamide gel electrophoresis (Fig. 2B) and stained with
Coomassie dye (myelin) or the proteins blotted to polyvinylidene
(PVDF) membrane followed by probing with antibodies to myelin
basic protein (MBP), proteolipid protein (PLP), or MOG in
western blots, or probing with fluorescent aptamers 3202, 3060 or
3064 in southwestern blots. Interestingly, whereas control aptamer
3202 showed no binding to myelin proteins, guanosine-rich
aptamers 3060 and 3064 bound specifically to certain proteins
(Fig. 2B). In particular, control aptamer 3060 and myelin-specific
aptamer 3064 both bound to three myelin proteins with apparent
molecular weights of 12.5 kDa, 18.5 kDa, and 23.8 kDa. Based on
western analysis and mass spectrometry of tryptic peptides these
proteins are PLP, the 18.5 kDa isoform of MBP, and MOG,
respectively. Importantly, myelin-specific aptamer 3064 uniquely
bound to myelin proteins with apparent molecular weights of
17 kDa and 21.5 kDa, identified as MBP isoforms containing
sequences encoded by MBP exon 2 [19]. Interestingly, it has
previously been suggested that immune reagents targeting exon 2
sequences can stimulate remyelination [20].
Figure 1. Selection of DNA aptamers specific for components of crude mouse myelin suspension. A. A pool of .1012 100-nucleotide
fluorescent (*) single-stranded DNA aptamers containing 60 nucleotides of random sequence is generated by a PCR and mixed with a suspension of
crude mouse myelin. Cycles of affinity purification and amplification (Figure S1, S2, S3, S4) yield long myelin-specific DNA aptamers from which active
sub-sequences can be derived. B. Deoxyguanosine-rich DNA aptamer 3064 specific for crude mouse myelin, shown folded as a putative
intramolecular G-quadruplex. C. Tetravalent complex of 3-biotinylated DNA aptamer (thin lines) with streptavidin (circles). D. Negative control
deoxyguanosine-rich DNA aptamer 3060 specific for chelated Nickel ions, shown as putative intramolecular G-quadruplex. E. Negative control
oligodeoxythymidylate 3202.
doi:10.1371/journal.pone.0039595.g001
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It is interesting to note that DNA aptamer 3064 is observed to
bind preferentially to an intact myelin suspension (Fig. 2A), while
both aptamers 3060 and 3064 show affinity for certain myelin
proteins after extraction of lipids and immobilization (Fig. 2B). As
discussed above, these results suggest that MBP sequences encoded
in exon 2 are targeted by aptamer 3064 and these sequences are
preferentially accessible in crude myelin suspensions. Extraction of
proteins for Southwestern blotting reveals other aptamer binding
sites that may not be accessible in intact myelin.
The binding properties of anti-myelin DNA aptamer 3064 are
similar to certain natural human IgM autoantibodies that promote
remyelination in the murine TMEV model of MS [8]. We
therefore tested intraperitoneal injection of anti-myelin DNA
aptamer 3064 compared to negative control aptamers 3060 and
3202. Aptamers were prepared as 39-biotin conjugates and
incubated in a 4:1 molar ratio (Fig. 3) with tetrameric streptavidin
to create conjugates with enhanced stability and biodistribution
[21] mimicking polyvalent antibodies. As shown in Fig. 3 (lanes 2,
6, 10), 4:1 aptamer:streptavidin incubation under these conditions
converts all monomeric aptamers to streptavidin complexes,
predominantly dimers.
To explore the biodistribution of DNA aptamer 39-biotin
conjugates, healthy FVB mice (Fig. 4 A, B) or TMEV-infected
SJL/J mice (Fig. 4 C, D) were treated by a single intraperitoneal
(i.p.) injection of 3064 aptamer conjugate (500 ml of 1 mM
conjugate solution; 0.5 nmol) or buffer alone and various tissues
were harvested 4 h or 12 h after injection. A PCR-based assay was
developed to detect the 3064 aptamer in tissue extracts. As shown
in Fig. 4, no aptamer signal was detected in animals injected with
buffer. For healthy FVB mice, aptamer was readily detected in
spleen, and to a lesser extent in kidney and liver, 4 h and 12 h
after injection. Aptamer could not be detected in heart, spinal
cord, lung, or brain under these conditions in healthy animals.
Remarkably, aptamer biodistribution was much enhanced in
TMEV-infected mice. Four hours after i.p. injection, DNA
aptamer could readily be detected in all tested tissues, including
brain and spinal cord (Fig. 4C). Detection after only 15 PCR cycles
indicated highest aptamer levels in organs of the abdomen and
thorax (Fig. 4D).
To study aptamer conjugate effects on CNS remyelination,
TMEV-infected SJL/J mice were treated by i.p. injection of
various aptamer conjugates (500 ml of 1 mM conjugate solution;
0.5 nmol) twice per week for a total of 10 doses starting 27 weeks
after Theiler’s virus infection. Central nervous system pathology
was then assessed 5 weeks after completion of aptamer injections.
Results are shown in Fig. 5 and Table 1. Spinal cords from all
mice in the study contained areas of chronic demyelination.
Infiltrating macrophages were present in several lesions. Remye-
lination is characterized by densely packed thin myelin sheaths in
relation to axon diameter. In mice treated with anti-myelin
aptamer 3064 more areas of dense remyelinated axons were found
(Fig. 5). For example, the top middle panel of Fig. 5 shows an area
of almost complete remyelination mediated by oligodendrocytes
located in the dorsal white matter column of the spinal cord of a
mouse treated with anti-myelin aptamer 3064. In mice treated
with control aptamers 3060 and 3202 dorsal column spinal cords
lesions contained fewer remyelinated axons. As shown in Table 1,
anti-myelin DNA aptamer 3064 induced remyelination in 35% of
experimental CNS lesions, compared to 4% and 9% remyelina-
tion after treatment with negative control aptamers 3202 and
3060, respectively. These statistically significant results indicate
selective enhancement of remyelination in vivo by anti-myelin DNA
aptamer treatment. Interestingly, animals injected with streptavi-
din and non-biotinylated aptamers 3064 or 3060 did not show
remyelination. This result suggests that aptamer 39 modification is
important for protection for nuclease attack and/or streptavidin
binding to form multivalent conjugates.
This aptamer-induced remyelination can be compared with
prior effects obtained using much larger and more labile human
IgM autoantibodies. In the latter case, a single dose (0.6 nmol)
IgM antibody promoted ,60% remyelination vs. 15% observed
for negative control [22]. The present result raises the possibility
that the observed remyelination activity of anti-myelin DNA
aptamers may also reflect direct interactions with lesions, though
this remains to be demonstrated. It has previously been shown that
Figure 2. DNA aptamer specificity characterization. A. Binding of fluorescent aptamers 3064 (filled circles), 3060 (filled squares) and 3202 (filled
triangles) to crude mouse myelin proteins detected by sedimentation of the insoluble myelin fraction. Mean and standard deviation are shown for
three repeats. B. Coomassie staining of crude myelin proteins (myelin; CBB) separated by SDS-polyacrylamide gel electrophoresis and results of
western and southwestern blotting with the indicated antibodies or fluorescent aptamers. Mobilities of molecular weight standards are indicated at
left and apparent molecular weights of aptamer-reactive proteins are indicated at right.
doi:10.1371/journal.pone.0039595.g002
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the abilities of certain natural IgM autoantibodies to stimulate cell
signaling and remyelination depend on the multivalent character
of the antibody structure [10]. It is noteworthy that the
formulation of biotinylated DNA aptamers with streptavidin was
intended to promote the formation of streptavidin-linked multi-
valent aptamer conjugates based on intramolecular aptamer
folding (Fig. 1B).
A number of important mechanistic issues remain to be better
understood for both antibodies and DNA aptamers that appear to
promote remyelination. These include the question of whether the
agents reach the demyelinated regions of the CNS and function
directly or indirectly, their actual target epitope(s), and their
detailed dose-response profiles. Evidence of spleen uptake in
healthy mice (Fig. 4) suggests the potential for a systemic immune
modulation mechanism, and direct effects on the CNS are possible
in TMEV-infected animals where the blood brain barrier is
apparently compromised by inflammation. Eventually it will also
be important to measure the functional impact of aptamer-
promoted remyelination in both mouse models and human trials.
The molecular mass of the anti-myelin DNA aptamer tested
here is ,13,000. If fully tetramerized with streptavidin (mass
,52,800) the resulting complex with mass ,104,800 is still about
10-fold smaller than the IgM antibodies we have previously shown
to promote remyelination. IgM antibodies are more difficult to
manufacture, are more likely to be immunogenic, but have been
shown to cross the blood-brain barrier. DNA aptamers can be
prepared by chemical synthesis, but future studies will be required
to assess the immunogenicity and tissue distribution of the aptamer
conjugates shown here to promote remyelination. These consid-
erations motivate further exploration of DNA aptamer reagents
for MS treatment.
Materials and Methods
Preparation of Crude Murine Myelin
CNS tissue from strain SJL mice (5 g) is homogenized in 0.32 M
sucrose containing 2 mM EGTA (pH 7.5) using a tissue grinder
followed by a Dounce homogenizer to yield a final volume of
100 ml. 17 ml of homogenate is layered onto 3 ml of 0.85 M
sucrose containing 2 mM EGTA and subjected to centrifugation
at 28,000 rpm for 1 h at 4uC. Material is collected from the
interface and homogenized in a total volume of 240 ml solution
containing 2 mM EGTA. After centrifugation, the pellet is
homogenized in 5 ml of a solution containing 10 mM EGTA,
the volume brought to 400 ml in 10 mM EGTA, and the solution
stirred for 15 min at 4uC. After centrifugation for 15 min at
10,000 rpm, homogenization and centrifugation is repeated. The
resulting pellet is homogenized in 100 ml of solution containing
0.85 M sucrose and 2 mM EGTA. The homogenate is overlayed
with 3 ml solution containing 0.32 M sucrose and 2 mM EGTA,
subjected to centrifugation at 28,000 rpm for 90 min. After
repeated homogenization and washing the myelin is isolated from
the 0.32 M/0.75 M interface of a discontinuous sucrose gradient,
washed with distilled water, and resuspended in 50 mM Tris-HCl
containing 2 mM EGTA.
In vitro Selection of DNA Aptamers
The initial round of selection employed 2.5 nmol (,161015
molecules) of random oligonucleotide library LJM-2772. Oligo-
nucleotides were heated to 90uC for 1 min in PBS containing
1 mM MgCl2, placed on ice for 15 min, and then incubated for
8 min at room temperature to allow folding. 200 mL mouse myelin
suspension (10 mg) was pelleted by centrifugation for 5 min at
6500 rpm (microcentrifuge). The pellet was washed twice by
resuspension in 500 mL binding buffer (20 mM Tris-HCl, pH 7.6,
10 mM NaCl, 0.5 mM KCl). The DNA library (5 mM in round 1,
300 nM in subsequent rounds) was then incubated for 30 min
with gentle agitation in a 500 mL binding reaction with 10 mg
myelin suspension in 500 mL binding buffer. The suspension and
bound aptamers was washed twice with 1 mL binding buffer by
6500 rpm centrifugation. To the pellet was added 400 mL 26PK
buffer (300 mM NaCl, 2.5 mM EDTA, 2% SDS), followed by
agitation, and extraction with 400 mL phenol:chloroform (1:1, v:v).
DNA was precipitated from the aqueous phase by addition of
ethanol. A portion of the recovered DNA was amplified by PCR to
establish the optimal number of amplification cycles. After the first
round, PCR was performed with a fluorescein-labeled primer,
allowing quantitation of library recovery by fluorescence spectros-
copy. The upper primer sequence was 59-F-ATAC2AGCT2AT2-
CA2T2 (F indicates fluorescein). The lower primer sequence was
59-A20-X2-AGAT2GCACT2ACTATCT (X indicates GLEN Re-
search spacer phosphoramidite 10-1909). PCR reactions (100 mL)
employed Taq DNA polymerase, primers at 10 mM final
concentration, and incubation for 5 min at 94uC, followed by
cycles of 30 s at 94uC, 30 s at 47uC, and 30 s at 72uC. A second
aliquot of recovered DNA was then amplified for the optimum
Figure 3. Formation of 39-biotinylated DNA aptamer multimers
by incubation with streptavidin. The indicated 59-fluoresceinated,
39-biotinylated DNA aptamers (lanes 4, 8, 12) were folded and then
incubated with different amounts of streptavidin to produce multimeric
aptamer complexes. Aptamer:streptavidin concentration ratios were 1:1
(lanes 1, 5, 9), 4:1 (lanes 2, 6, 10), and 20:1 (lanes 3, 7, 11). Mobilities of
aptamer monomer and complexes containing one to four aptamers (1–
4; see Fig. 1C) are indicated. Note that complexes with two bound
aptamers display two distinct mobilities due to cis vs. trans binding
arrangements on the streptavidin tetramer.
doi:10.1371/journal.pone.0039595.g003
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Figure 4. Tissue distribution of DNA aptamer 3064 conjugated to biotin 4 h (A, C, D) or 12 h (B) after i.p. injection into healthy FVB
mice (A, B) or TMEV-infected SJL/J mice (C, D). Control animals (‘‘buffer injection’’ group in each panel) were injected with the equivalent buffer
solution lacking aptamer conjugate. Conjugates were extracted from duplicate mice (middle and right group in each panel) and detected by the
indicated number of PCR cycles as described in Methods. Each lane reflects PCR products amplified from extract representing 8.25 mg original tissue
wet weight. Arrows indicate position of 120-bp aptamer-specific PCR product. Numbering: 1, heart; 2, spinal cord; 3, spleen; 4, lung; 5, brain; 6, kidney;
7, liver; 8, water control. A nonspecific prominent PCR product (higher mobility than the aptamer-specific product) results from primer-primer
interactions.
doi:10.1371/journal.pone.0039595.g004
Figure 5. Light photomicrographs demonstrating examples of TMEV-mediated spinal cord demyelination (lower panels) and
remyelination (upper panels) in mice treated with the indicated DNA aptamers. Scale bar in lower right panel is 100 micrometers. After
blinded micrograph review of specimens from control and aptamer-treated animals the percent of spinal cord quadrants showing demyelination or
remyelination was determined as reported in Table 1.
doi:10.1371/journal.pone.0039595.g005
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number of cycles to prepare aptamer for the next selection round.
Single-stranded fluorescent aptamer was obtained by precipitation
of PCR reactions from ethanol, followed by denaturing polyacryl-
amide gel electrophoresis. The fluorescent DNA band was cut
from the gel, diced, and eluted in TE buffer at 37uC for 2–12 h,
followed by precipitation from ethanol and quantitation by UV
spectrometry. After 11 selection cycles, PCR was performed and
the resulting duplex DNA was ligated into the pGEM-Teasy
cloning vector (Promega, Madison, WI), cloned, and sequenced.
Aptamer Specificity Characterization
To promote intramolecular folding, aptamer stock solutions
(5 mM) in PBS were heated to 90uC and MgCl2 was then added to
a final concentration of 1 mM and solutions were allowed to cool
room temperature. Myelin stock was diluted in PBS and sonicated
on ice. Fluorescent folded aptamers were added to different
amounts of myelin suspension and incubated at 37u C for 3 h.
Insoluble material with bound aptamers was recovered by 30 s
centrifugation in the microcentrifuge. The pellet was washed with
100 mL PBS and again recovered by centrifugation. After phenol
extraction and ethanol precipitation fluorescent aptamers were
quantitated in black plastic 96-well plates using a Typhoon
Fluorescent Imaging system (GE). For Southwestern blotting,
15 mg crude myelin protein was separated in each lane of a 10%
Bis-Tris SDS polyacrylamide gel in MES buffer. After electro-
phoresis, duplicate lanes were either stained with Coomassie blue
dye or transferred to PVDF membrane by electroblotting. Western
blotting was performed by standard methods using antibodies with
the indicated specificities. For southwestern blots, membranes
were blocked for 30 min at 37u C in TBST buffer containing with
1% BSA, 10% non-fat dry milk, 2 mg/mL sonicated and heat-
denatured salmon testis DNA, and Tween 20 detergent. Folded
fluorescent aptamers (5 mM final concentration) were then added
in PBS containing 1 mM MgCl2 and incubated with PVDF
membranes for 14 h followed by washing in TBST buffer
containing Tween 20 detergent and then washing with 0.56
TBE buffer. Fluorescein fluorescence was then detected on
membranes using the Typhoon Fluorescent Imaging system
(GE). Tryptic peptide mass fingerprinting was performed in the
Mayo Clinic Proteomics Center.
Mouse Model
All studies conformed to Mayo Clinic and National Institutes of
Health animal use guidelines and were reviewed and approved by
the Mayo Clinic Institutional Animal Care and Use Committee as
protocol A29509. Eight-week-old female SJL/J mice (Jackson
Laboratories, Bar Harbor, ME) received a single intracerebral
injection of 26105 plaque-forming units of the Daniel’s strain of
Theiler’s Myeloencephilitus Virus (TMEV) in Dulbecco’s phos-
phate buffered saline (DPBS; 10 mL). The resulting encephalitic-
like infection resulting in greater than 98% incidence of
demyelination with increasing neurologic deficits progressing over
several months [23]. Animals used for remyelination studies in this
report were chronically demyelinated by 6 months post infection
with clear neurologic deficits. To assemble treatment groups in
cages of five mice each, all mice to be treated were combined in a
large container and then distributed equally based on the level of
disability. The extent of mouse disability was determined by
examination of the mouse coat color, a reflection of the ability to
self-groom, gait and the ability to right when placed on the dorsal
side.
Aptamer Treatment
DNA oligonucleotides LJM-3064b (40 nt), LJM-3060b (43 nt)
and LJM-3202b (40 nt) were synthesized DMT-off at 1 mmol scale
using 39 biotinTEG control pore glass support (Glen Research 20-
2955). Oligonucleotides were cleaved from the support and
deprotected in hot ammonia, then dried and purified by reverse
phase HPLC and sterilized by precipitation from ethanol. Groups
of mice received 500-mL intraperitoneal (i.p.) injections of the 39
biotin conjugated aptamer (1 mM) combined with streptavidin
(0.25 mM) in Calcium-free D-PBS (Invitrogen) supplemented with
magnesium chloride (1 mM). Injections were twice per week for 5
weeks. Briefly, sterile aptamer solution (1 mM) in Calcium-free D-
PBS supplemented with MgCl2 (1 mM) was heated to 90u C for
1 min, placed on ice for 15 min, and then incubated for 8 min at
room temperature to allow aptamer folding. Streptavidin stock
solution (Jackson Immune Research; 1 mg/mL; 18 mM in
Calcium-free D-PBS) was added to a final concentration of
0.25 mM and incubated with gentle agitation for 30 min at 37u C
immediately prior to intraperitoneal injection into mice. The final
aptamer injection solution (500 mL) contained streptavidin:
13.8 mg/mL (0.25 mM), aptamer-39-Biotin: 13.4 (12.7–14.2) mg/
mL (1.2–1.5 mM) in Calcium-free D-PBS supplemented with
MgCl2 (1 mM). Each treatment therefore consisted of 6.9 mg
(125 pmol) streptavidin, 6.7 mg (500 pmol) aptamer-39-biotin, and
47.6 mg (500 mmol) MgCl2.
Aptamer Biodistribution
Healthy FVB mice (38 d) or TMEV-infected SJL/J mice (6
months post infection) were used for aptamer biodistribution
studies. DNA aptamer-streptavidin conjugates were extracted 4 h
or 12 h after a single i.p. injection of 500 mL 1 mM biotinylated
DNA aptamer 3064 prepared as low-order conjugates conjugate
with streptavidin in Calcium-free D-PBS containing 1 mM
MgCl2. Control animals were injected with the equivalent solution
lacking aptamer conjugate. Animals were killed by sedation with
isoflurane vapors followed by IP injection of 0.1 mL sodium
barbital (constituting a lethal dose). Tissues (80–150 mg/organ)-
were harvested and homogenized in Qiagen plasmid preparation
buffer P1 (300 mL), followed by addition of Qiagen plasmid
Table 1. Remyelination in vivo after DNA aptamer treatment1.
aptamer biotin streptavidin N Demyelination remyelination
(specificity)
3064 + + 10 41.166.4 34.966.1
(myelin)
3060 + + 7 38.268.7 8.864.5
(Nickel)
3202 + + 8 51.8626.4 4.262.3
(dT40
control)
3064 – + 9 42.065.8 8.563.4
(myelin)
3060 – + 8 50.064.6 10.364.4
(Nickel)
1Table indicates lesion status, by animal, after blinded review of
neuropathology. N: number of mice. Data express percentage of spinal cord
quadrants showing at least 75% of the lesion was remyelinated (mean +/2
SEM). Statistical comparisons: P,0.002 remyelination - (ANOVA on Ranks).
Dunn’s comparison to 3202 (control) showed statistical difference (p,0.05)
against 3064 with biotin/streptavidin. There was no statistically significant
difference in remyelination between 3202 control and 3064 without biotin.
doi:10.1371/journal.pone.0039595.t001
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preparation buffer P2 (300 mL), and then precipitation of genomic
DNA, proteins and cellular debris by addition of Qiagen plasmid
preparation buffer P3 (300 mL). After centrifugation, the clarified
supernatant was treated with proteinase K (0.1 mg/ml final
concentration) overnight at 55u and nucleic acids precipitated by
addition of an equal volume of isopropanol and centrifugation.
DNA aptamer 3064 was detected by PCR using primers:
LJM-4556 (59-CTAGACTAGA2GCTGAGCTGCTAGAC-
TAGA2GCTGAGCTG4TCG2CG3TG3) and LJM-4557 (59-
ACGT2ACGT2ATGACATGACACGT2ACGT2ATGACAT-
GACAC3AGAGACA2GAC2AC) and Failsafe Kit (Epicentre,
Madison, WI) condition J or L with the first five cycles annealed
at 40u C and subsequent cycles annealed at 60u C. An aptamer-
specific PCR product of 120 bp is generated from 40-nucleotide
aptamer 3064.
Spinal Cord Morphometry
Mice were euthanized with sodium pentobarbital and perfused
intracardially with Trump’s fixative (phosphate-buffered 4%
formaldehyde/1% glutaraldehyde, pH 7.4). Spinal cords were
removed, cut into 1 mm blocks and every third block fixed and
stained with osmium tetroxide and embedded in araldite plastic
(Polysciences, Warrington, PA). One-micrometer-thick cross-sec-
tions were cut from each block, mounted onto glass slides, and
stained with 4% paraphenylene-diamine to visualize myelin [24].
10–12 cross-sections represent samples from the cervical, thoracic,
lumbar, and sacral spinal cord. Neuropathology to characterize
extent of lesion remyelination was performed according to a
blinded protocol. Three investigators (MF, BW and AW)
examined the sections independently without knowledge of
treatment groups. For blinded grading, each spinal cord section
was divided visually into four quadrants based on morphological
symmetry and examined by bright field microscopy at 1006 and
2006 total magnification using an Olympus Provis microscope.
Demyelinated areas were characterized by denuded axons and
inflammatory cell infiltrates. Demyelinated areas with remyelina-
tion were characterized by thin myelin sheaths compared with the
thicker, intact myelin sheaths. The spinal cord white matter was
scored as normal, demyelinated with no remyelination, or
demyelinated with remyelination [22]. Partial quadrants were
excluded. Lesions were judged to be remyelinated when the lesion
was 75–100% repaired. Remyelinated lesions below this threshold
were scored as negative. Data were not assembled into treatment
groups until all slides in a given study were graded. Demyelination
for each mouse was calculated as a percentage based on the
number of spinal cord quadrants with demyelination, which
includes those quadrants with demyelination and repair, divided
by the total number of quadrants scored. Remyelination for each
mouse was calculated as a percentage based on the number of
demyelinated quadrants above threshold remyelination divided by
the number of quadrants with demyelination. Data for percentage
spinal cord demyelination and remyelination were compared
across groups using one-way ANOVA on ranks. When a
significant difference (P,0.05) was identified, a pairwise compar-
ison of aptamer-treated groups with the aptamer-control and
untreated control groups was performed. Statistical analysis and
plots were performed using SigmaStat and SigmaPlot.
Supporting Information
Figure S1 Schematic of approach and results. A vast
random pool of ,1015 single-stranded DNA molecules is
generated. DNA molecules (aptamers) are selected for binding to
components of a crude mouse myelin suspension. After cloning
and identification of the DNA subsequence important for myelin
binding, DNA aptamers are injected into the peritoneal cavities of
mice with demyelinating CNS lesions induced by Theiler’s
encephalomyelitis virus infection. Immunopathology is monitored
7–9 months after infection to detect enhanced CNS remyelination.
(TIFF)
Figure S2 Chemical modifications of DNA aptamers
relevant to this work. A. 59-fluorescein modification present
for in vitro selection and binding studies. B. 39 biotin modification
present in aptamers used for in vivo injection.
(TIFF)
Figure S3 Results of in vitro selection of DNA aptamer
pools over 10–11 rounds of selection and amplification.
Targets were myelin oligodendrocyte glycoprotein (MOG) immo-
bilized on Ni-NTA magnetic beads (filled circles) or suspension of
crude mouse myelin in buffer (open circles). MOG selections gave
rise to aptamer 3060 (selective for chelated Nickel beads). Myelin
selections gave rise to aptamer 3064.
(TIFF)
Figure S4 Sequences of anti-myelin DNA aptamers and
derived sub-sequences. A. Initial sequences of DNA aptamers
after cloning. Sequences derived from random regions are in
black. Fixed sequences for PCR primer binding are in blue. The
top three identical sequences correspond to aptamer 3028. B.
Derivation of aptamer sub-sequences from anti-myelin aptamer
3028. Aptamer 3064 was selected for further testing in this work.
(TIFF)
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